Recombinant Human EPHA2 Protein, MYC/DDK-tagged, C13 and N15-labeled
|Product Overview :||EPHA2 MS Standard C13 and N15-labeled recombinant protein (NP_004422) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.|
- Gene Information
- Related Products
|Description :||This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders. [provided by RefSeq, May 2010]|
|Molecular Mass :||108.1 kDa|
|AA Sequence :||MELQAARACFALLWGCALAAAAAAQ GKEVVLLDFAAAGGELGWLTHPYGK GWDLMQNIMNDMPIYMYSVCNVMSG DQDNWLRTNWVYRGEAERIFIELKF TVRDCNSFPGGASSCKETFNLYYAE SDLDYGTNFQKRLFTKIDTIAPDEI TVSSDFEARHVKLNVEERSVGPLTR KGFYLAFQDIGACVALLSVRVYYKK CPELLQGLAHFPETIAGSDAPSLAT VAGTCVDHAVVPPGGEEPRMHCAVD GEWLVPIGQCLCQAGYEKVEDACQA CSPGFFKFEASESPCLECPEHTLPS PEGATSCECEEGFFRAPQDPASMPC TRPPSAPHYLTAVGMGAKVELRWTP PQDSGGREDIVYSVTCEQCWPESGE CGPCEASVRYSEPPHGLTRTSVTVS DLEPHMNYTFTVEARNGVSGLVTSR SFRTASVSINQTEPPKVRLEGRSTT SLSVSWSIPPPQQSRVWKYEVTYRK KGDSNSYNVRRTEGFSVTLDDLAPD TTYLVQVQALTQEGQGAGSKVHEFQ TLSPEGSGNLAVIGGVAVGVVLLLV LAGVGFFIHRRRKNQRARQSPEDVY FSKSEQLKPLKTYVDPHTYEDPNQA VLKFTTEIHPSCVTRQKVIGAGEFG EVYKGMLKTSSGKKEVPVAIKTLKA GYTEKQRVDFLGEAGIMGQFSHHNI IRLEGVISKYKPMMIITEYMENGAL DKFLREKDGEFSVLQLVGMLRGIAA GMKYLANMNYVHRDLAARNILVNSN LVCKVSDFGLSRVLEDDPEATYTTS GGKIPIRWTAPEAISYRKFTSASDV WSFGIVMWEVMTYGERPYWELSNHE VMKAINDGFRLPTPMDCPSAIYQLM MQCWQQERARRPKFADIVSILDKLI RAPDSLKTLADFDPRVSIRLPSTSG SEGVPFRTVSEWLESIKMQQYTEHF MAAGYTAIEKVVQMTNDDIKRIGVR LPGHQKRIAYSLLGLKDQVNTVGIP ITRTRPLEQKLISEEDLAANDILDY KDDDDKV|
|Purity :||> 80% as determined by SDS-PAGE and Coomassie blue staining|
|Stability :||Stable for 3 months from receipt of products under proper storage and handling conditions.|
|Storage :||Store at -80 centigrade. Avoid repeated freeze-thaw cycles.|
|Concentration :||50 μg/mL as determined by BCA|
|Storage Buffer :||100 mM glycine, 25 mM Tris-HCl, pH 7.3.|
|Gene Name :||EPHA2 EPH receptor A2 [ Homo sapiens (human) ]|
|Official Symbol :||EPHA2|
|Synonyms :||EPHA2; EPH receptor A2; ECK, EphA2; ephrin type-A receptor 2; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK; epithelial cell receptor protein tyrosine kinase; ECK; CTPA; ARCC2; CTPP1;|
|Gene ID :||1969|
|mRNA Refseq :||NM_004431|
|Protein Refseq :||NP_004422|
|UniProt ID :||P29317|
|◆ Recombinant Protein|
|EPHA2-1903H||Recombinant Human EPHA2 Protein, MYC/DDK-tagged||+Inquiry|
|EPHA2-2515H||Recombinant Human EPHA2 Protein (28-328 aa), His-Myc-tagged||+Inquiry|
|EPHA2-3378H||Recombinant Human EPHA2 Protein, GST-tagged||+Inquiry|
|EPHA2-0985H||Recombinant Human EPHA2 Protein (R561-I976), Tag Free||+Inquiry|
|Epha2-954M||Recombinant Mouse Epha2 Protein, MYC/DDK-tagged||+Inquiry|
|EPHA2-001HCL||Recombinant Human EPHA2 cell lysate||+Inquiry|
|EPHA2-1072HCL||Recombinant Human EPHA2 cell lysate||+Inquiry|
|EPHA2-2138MCL||Recombinant Mouse EPHA2 cell lysate||+Inquiry|
|◆ Assay kits|
|Kit-0326||EphA2 Kinase (Human) Assay/Inhibitor Screening Assay Kit||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.
The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.
In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.
Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.
Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.
EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.
Customer Reviews (3)Write a review
The protein has low cytotoxicity. -
EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good. -
Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well. -
Ask a Question for All EPHA2 Products
Required fields are marked with *
My Review for All EPHA2 Products
Required fields are marked with *